Bridge Biotherapeutics, Inc. (KOSDAQ: 288330)
South Korea
· Delayed Price · Currency is KRW 5,030.00
+210.00 (4.36%)
Oct 11, 2024, 10:09 AM KST
Bridge Biotherapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Operating Revenue | - | 100 | 3,024 | 1,924 | 6,340 | 58,283 | Upgrade
|
| Other Revenue | -0 | -0 | - | - | - | - | Upgrade
|
| Revenue | -0 | 100 | 3,024 | 1,924 | 6,340 | 58,283 | Upgrade
|
| Revenue Growth (YoY) | - | -96.69% | 57.15% | -69.65% | -89.12% | - | Upgrade
|
| Cost of Revenue | 83.23 | 82.94 | 179.53 | 11.09 | 7,464 | 36,016 | Upgrade
|
| Gross Profit | -83.23 | 17.06 | 2,844 | 1,913 | -1,124 | 22,267 | Upgrade
|
| Selling, General & Admin | 10,862 | 13,477 | 13,033 | 10,304 | 5,649 | 6,116 | Upgrade
|
| Research & Development | 17,872 | 25,299 | 32,093 | 17,517 | 12,373 | 15,190 | Upgrade
|
| Other Operating Expenses | 190.76 | 166.06 | 141.42 | 101.68 | 74.05 | 54.56 | Upgrade
|
| Operating Expenses | 30,372 | 40,366 | 46,346 | 28,305 | 18,454 | 21,650 | Upgrade
|
| Operating Income | -30,455 | -40,349 | -43,501 | -26,392 | -19,578 | 617.19 | Upgrade
|
| Interest Expense | -170.65 | -170.65 | -64.75 | -7.53 | -6.34 | -2,741 | Upgrade
|
| Interest & Investment Income | 1,034 | 1,034 | 950.97 | 350.68 | 208.73 | 221.92 | Upgrade
|
| Currency Exchange Gain (Loss) | 140.18 | 140.18 | -203.79 | 65.9 | 107.46 | 494.79 | Upgrade
|
| Other Non Operating Income (Expenses) | -3,940 | -3,083 | 1,068 | -295.88 | -149.94 | 8,586 | Upgrade
|
| EBT Excluding Unusual Items | -33,391 | -42,428 | -41,751 | -26,279 | -19,418 | 7,179 | Upgrade
|
| Gain (Loss) on Sale of Investments | -26.78 | -26.78 | 51.29 | 0.3 | 186.87 | 69.18 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -1.05 | -22.27 | Upgrade
|
| Pretax Income | -33,418 | -42,455 | -41,700 | -26,278 | -19,232 | 7,226 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | 5,902 | Upgrade
|
| Earnings From Continuing Operations | -33,418 | -42,455 | -41,700 | -26,278 | -19,232 | 1,325 | Upgrade
|
| Minority Interest in Earnings | 306.4 | 134.36 | - | - | - | - | Upgrade
|
| Net Income | -33,112 | -42,321 | -41,700 | -26,278 | -19,232 | 1,325 | Upgrade
|
| Net Income to Common | -33,112 | -42,321 | -41,700 | -26,278 | -19,232 | 1,325 | Upgrade
|
| Shares Outstanding (Basic) | 27 | 25 | 24 | 23 | 23 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 27 | 25 | 24 | 23 | 23 | 12 | Upgrade
|
| Shares Change (YoY) | 13.11% | 3.58% | 1.56% | 2.53% | 96.53% | 64.86% | Upgrade
|
| EPS (Basic) | -1225.14 | -1716.23 | -1751.63 | -1121.11 | -841.28 | 118.27 | Upgrade
|
| EPS (Diluted) | -1225.32 | -1716.23 | -1751.67 | -1121.11 | -841.67 | 114.30 | Upgrade
|
| Free Cash Flow | -27,492 | -32,095 | -40,619 | -21,293 | -13,117 | -8,191 | Upgrade
|
| Free Cash Flow Per Share | -1017.19 | -1301.54 | -1706.25 | -908.42 | -573.78 | -704.16 | Upgrade
|
| Gross Margin | - | 17.06% | 94.06% | 99.42% | -17.73% | 38.21% | Upgrade
|
| Operating Margin | - | -40349.43% | -1438.66% | -1371.60% | -308.81% | 1.06% | Upgrade
|
| Profit Margin | - | -42321.05% | -1379.08% | -1365.70% | -303.35% | 2.27% | Upgrade
|
| Free Cash Flow Margin | - | -32095.05% | -1343.35% | -1106.61% | -206.90% | -14.05% | Upgrade
|
| EBITDA | -29,008 | -38,925 | -42,423 | -26,010 | -19,220 | 1,069 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | 1.83% | Upgrade
|
| D&A For EBITDA | 1,447 | 1,424 | 1,078 | 381.46 | 357.87 | 451.41 | Upgrade
|
| EBIT | -30,455 | -40,349 | -43,501 | -26,392 | -19,578 | 617.19 | Upgrade
|
| EBIT Margin | - | - | - | - | - | 1.06% | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 81.67% | Upgrade
|
| Advertising Expenses | - | 31.39 | 28.01 | 10.95 | 29.98 | 100.76 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.